Literature DB >> 15171487

Acute oxcarbazepine and atomoxetine overdose with quetiapine.

Michael J Barker1, John G Benitez, Sharon Ternullo, Gregory A Juhl.   

Abstract

We present a case of acute oxcarbazepine and atomoxetine overdose combined with excess quetiapine in a 19-y-old male. The patient ingested approximately 36 g oxcarbazepine (514 mg/kg), 1.2 g atomoxetine (17 mg/kg), and 9 mg Quetiapine (128 mg/kg). Central nervous system (CNS) depression with initial unresponsiveness developed within 1 h of ingestion, necessitating intubation for airway protection. Despite aggressive therapy with whole bowel irrigation and charcoal administration, the patient's somnolence persisted for 4 d, punctuated by occasional violent outbursts. Prolonged QTc was noted initially, but normalized within 4 d. This case suggests that acute overdose of oxcarbazepine and atomoxetine combined with quetiapine is associated with rapid and prolonged CNS depression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15171487

Source DB:  PubMed          Journal:  Vet Hum Toxicol        ISSN: 0145-6296


  9 in total

1.  Acute oxcarbazepine overdose in an autistic boy.

Authors:  Maura Pedrini; Antoni Noguera; Joan Vinent; Mercè Torra; Rafael Jiménez
Journal:  Br J Clin Pharmacol       Date:  2009-02-26       Impact factor: 4.335

2.  Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers.

Authors:  Corina Loghin; Harry Haber; Charles M Beasley; Prajakti A Kothare; Lynnette Kauffman; John April; Ling Jin; Albert J Allen; Malcolm I Mitchell
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

3.  Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine.

Authors:  Toru Kobayashi; Kazuo Washiyama; Kazutaka Ikeda
Journal:  Neuropsychopharmacology       Date:  2010-03-10       Impact factor: 7.853

Review 4.  Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Authors:  Jose Martinez-Raga; Carlos Knecht; Nestor Szerman; María I Martinez
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

Review 5.  Attention-deficit/hyperactivity disorder genomics: update for clinicians.

Authors:  Josephine Elia; Jillan Sackett; Terri Turner; Martin Schardt; Shih-Ching Tang; Nicole Kurtz; Maura Dunfey; Nadia A McFarlane; Aita Susi; David Danish; Alice Li; Jenelle Nissley-Tsiopinis; Karin Borgmann-Winter
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

Review 6.  A systematic review of cardiovascular effects after atypical antipsychotic medication overdose.

Authors:  Hock Heng Tan; Jason Hoppe; Kennon Heard
Journal:  Am J Emerg Med       Date:  2009-06       Impact factor: 2.469

Review 7.  Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary.

Authors:  Mary M Robertson
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-02       Impact factor: 4.785

Review 8.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

9.  Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents.

Authors:  Daniel Scherer; David Hassel; Ramona Bloehs; Edgar Zitron; Katharina von Löwenstern; Claudia Seyler; Dierk Thomas; Franziska Konrad; Heiner F Bürgers; Gunnar Seemann; Wolfgang Rottbauer; Hugo A Katus; Christoph A Karle; Eberhard P Scholz
Journal:  Br J Pharmacol       Date:  2009-01-16       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.